Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Cash & Current Investments (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Cash & Current Investments for 13 consecutive years, with $203.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Current Investments rose 94.05% to $203.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $203.8 million, a 94.05% increase, with the full-year FY2025 number at $203.8 million, up 94.05% from a year prior.
  • Cash & Current Investments was $203.8 million for Q4 2025 at Madrigal Pharmaceuticals, down from $1.1 billion in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $1.1 billion in Q3 2025 to a low of $99.9 million in Q4 2023.
  • A 5-year average of $463.9 million and a median of $303.2 million in 2021 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: plummeted 72.15% in 2023, then skyrocketed 329.79% in 2024.
  • Madrigal Pharmaceuticals' Cash & Current Investments stood at $270.3 million in 2021, then surged by 32.71% to $358.8 million in 2022, then crashed by 72.15% to $99.9 million in 2023, then rose by 5.11% to $105.0 million in 2024, then skyrocketed by 94.05% to $203.8 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Cash & Current Investments are $203.8 million (Q4 2025), $1.1 billion (Q3 2025), and $797.0 million (Q2 2025).